The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention.
Authors:Raymond C Rosen|||Joseph A Catania|||Anke A Ehrhardt|||Arthur L Burnett|||Tom F Lue|||Kevin McKenna|||Julia R Heiman|||Sandy Schwarcz|||David G Ostrow|||Sabina Hirshfield|||David W Purcell|||William A Fisher|||Ron Stall|||Perry N Halkitis|||David M Latini|||Jonathan Elford|||Edward O Laumann|||Freya L Sonenstein|||David J Greenblatt|||Robert A Kloner|||Jay Lee|||David Malebranche|||Erick Janssen|||Rafael Diaz|||Jeffrey D Klausner|||Arthur L Caplan|||Graham Jackson|||Ridwan Shabsigh|||Jag H Khalsa|||David M Stoff
Journal: The journal of sexual medicine
Publication Type: Congress
Date: 2006
DOI: 10.1111/j.1743-6109.2006.00323.x
ID: 17100928
Affiliations:
Affiliations
Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, NJ, and New England Research Institutes, Watertown, MA. Electronic address: rrosen@neriscience.com.|||Center for AIDS Prevention Studies, Department of Medicine, San Francisco, CA.|||HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, Columbia University, New York, NY.|||Department of Urology, The Johns Hopkins Hospital, Baltimore, MD.|||Department of Urology, University of California, San Francisco, CA.|||Departments of Physiology and Urology, Northwestern University Medical School, Chicago, IL.|||Kinsey Institute for Research in Sex, Gender and Reproduction, Indiana University, Bloomington, IN.|||HIV/AIDS Statistics and Epidemiology, San Francisco Public Health Department, San Francisco, CA.|||David Ostrow & Associates, Lakewood, IL.|||Medical and Health Research Association, New York, NY.|||Prevention Research Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.|||Departments of Psychology and Obstetrics and Gynecology, University of Western Ontario, London, Ontario, Canada.|||Department of Behavioral and Community Health Sciences, University of Pittsburgh, Pittsburgh, PA.|||Center for Health, Identity, Behavior and Prevention Studies (CHIBPS), New York University, New York, NY.|||Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.|||City University, Institute of Health Sciences, UK.|||Department of Sociology, University of Chicago, Chicago, IL.|||Center for Adolescent Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.|||Department of Pharmacology & Experimental Therapeutics, Tufts University, Boston, MA.|||Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.|||Private Practice, Calgary Alberta, Canada.|||Department of Medicine, Emory University, Atlanta, GA.|||Kinsey Institute for Research in Sex, Gender and Reproduction, Indiana University, Bloomington, IN.|||Cesar Chavez Institute, San Francisco State University, San Francisco, CA.|||STD Prevention and Control Services, San Francisco Department of Public Health, San Francisco, CA.|||Center for Bioethics, University of Pennsylvania, Philadelphia, PA, USA.|||Saint Thomas Hospital, London, UK.|||Department of Urology, Columbia Presbyterian Medical Center, Columbia University, New York, NY.|||Medical Consequences Branch, National Institute on Drug Abuse, Bethesda, MD.|||Center for Mental Health Research on AIDS, National Institute of Mental Health, Bethesda, MD, USA.
Abstract
Recent reports have linked the use of phosphodiesterase type 5 (PDE-5) inhibitors with increased rates of high-risk sexual behavior and HIV transmission in some individuals.